BACE1

BACE1

B-site amyloid precursor protein (APP) cleaving enzyme. An aspartic-acid protease encoded by BACE1 on chromosome 11q23.2.-q23.3, which is linked to the pathogenesis of Alzheimer's disease and the formation of myelin sheaths in peripheral nerve cells. BACE1 is a transmembrane aspartic protease (beta-secretase) found in the Golgi apparatus, trans-Golgi network, secretory vesicles, and endosomes. It cleaves amyloid precursor protein (APP) in the brain into amyloid beta peptide, a major component of the amyloid plaques of Alzheimer's disease (AD), the deposition of which is the central pathology in AD, for which BACE1 is potential therapeutic target.
Mentioned in ?
References in periodicals archive ?
THOUSAND OAKS, Calif., July 11, 2019/PRNewswire/ -- Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program.
THOUSAND OAKS, Calif., July 11, 2019/PRNewswire/--Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program.
Switzerland-based Novartis, United States-based Amgen and Banner Alzheimer's Institute have decided to stop the clinical programme with BACE1 inhibitor, CNP520 (umibecestat), for the prevention of Alzheimer's disease, it was reported on Friday.
Amgen, Novartis and Banner Alzheimer's Institute announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program.
(Alliance News) - Swiss pharma firm Novartis AG, American biotechnology company Amgen Inc and Banner Alzheimer's Institute on Thursday announced the partners will discontinue investigation of the BACE1 inhibitor CNP520 in two pivotal second and third phase studies.
Amgen (AMGN), Novartis (NVS) and Banner Alzheimer's Institute announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program.
Indeed, the glycan is carried by several brain-derived proteins such as prostaglandin D synthetase (16) and [beta]- secretase (or BACE1).
The beta-site APP-cleaving enzyme 1 (BACE1) has been identified as an important [beta]-secretase in that process (9).
Zlokovic and colleagues found that 3K3A-APC protects the brain by preventing nerve cells from producing an enzyme called BACE1 that is required to produce amyloid-EaA-.
Moreover, leptin also decreases the BACE1 ([beta]-site APP cleaving enzyme 1) activity in SH-SY5Y cell line (10).
Regulatory relationships were seen linking viral abundance and modulators of APP metabolism; HHV-6A induced APBB2, APPBP2, BIN1, BACE1, CLU, PICALM, and PSEN1.